Reduced neutralization of SARS-CoV-2 Omicron variant by BNT162b2 vaccinees' sera: a preliminary evaluation
Emerg Microbes Infect
.
2022 Dec;11(1):790-792.
doi: 10.1080/22221751.2022.2045878.
Authors
D Mileto
1
,
V Micheli
1
,
C Fenizia
2
3
,
M Cutrera
1
,
G Gagliardi
1
,
A Mancon
1
,
F Bracchitta
1
,
A De Silvestri
4
,
G Rizzardini
5
,
A Lombardi
1
,
M Biasin
2
,
M R Gismondo
1
Affiliations
1
Laboratory of Clinical Microbiology, Virology and Bioemergencies, ASST Fatebenefratelli Sacco, L. Sacco University Hospital, Milan, Italy.
2
Department of Biomedical and Clinical Sciences L. Sacco, University of Milan, Milan, Italy.
3
Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.
4
Clinical Epidemiology and Biometeric Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
5
Division of Infectious Diseases, ASST Fatebenefratelli Sacco, L. Sacco University Hospital, Milan, Italy.
PMID:
35196967
PMCID:
PMC8920392
DOI:
10.1080/22221751.2022.2045878
No abstract available
Publication types
Letter
MeSH terms
Antibodies, Neutralizing
BNT162 Vaccine
COVID-19*
Humans
SARS-CoV-2*
Substances
Antibodies, Neutralizing
BNT162 Vaccine
Supplementary concepts
SARS-CoV-2 variants